PARIS – July 10, 2019 – The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for isatuximab for the treatment of patients with relapsed/refractory multiple myeloma (RRMM). The target…Original Article
FDA to Review Isatuximab as a Potential Treatment for Relapsed/Refractory Multiple Myeloma
